SARS-CoV-2 Isolates and Reagents

NIAID’s efforts to establish a repository of SARS-CoV-2 variants through BEI Resources has been recognized for promoting the global sharing of virus isolates during the pandemic to support development of diagnostics, vaccines and therapeutics.1

The BEI Resources catalog contains more than 380 SARS-CoV-2 isolates and unique reagents representing ten Variants Being Monitored and the Variant of Concern Omicron. Recent additions include monoclonal antibodies to SARS-CoV-2 Spike glycoprotein receptor binding domain (RBD) and an isolate of lineage BA.5, now the dominant lineage in the United States.2

For an up-to-date listing of all currently available SARS-CoV-2 isolates, please visit the SARS-CoV-2 resource page on the BEI Resources website.


BEI Resources 

Recent SARS-CoV-2 Isolates


Isolate hCoV-19/USA/PHC205/2021 (Lineage B.1.1.519)


Isolate hCoV-19/USA/VA-FBCH_675/2021 (Lineage AY4.2; Delta Variant)


Isolate hCoV-19/France/PAC-IHUMI-6070/2022 (Lineage AY.4 plus Omicron; XD Variant)


Isolate hCoV-19/France/PAC-IHUMI-6070/2022 p2 (Lineage AY.4 plus Omicron; XD Variant)


Isolate hCoV-19/USA/NY-MSHSPSP-PV56475/2022 (Lineage BA.2.12.1; Omicron Variant)


Isolate hCoV-19/South Africa/CERI-KRISP-K040013/2022 (Lineage BA.5; Omicron Variant)

BEI Resources

 Recent SARS-CoV-2 Reagents


Monoclonal Anti-SARS-CoV-2 Spike Glycoprotein RBD, Clone 2TP1D10 (produced in vitro)


Monoclonal Anti-SARS-CoV-2 Spike Glycoprotein RBD, Clone 2TP1E6 (produced in vitro)


Monoclonal Anti-SARS-CoV-2 Spike Glycoprotein RBD, Clone 2TP1F2 (produced in vitro)


Monoclonal Anti-SARS-CoV-2 Spike Glycoprotein RBD, Clone 2TP2F2 (produced in vitro)


Spike Glycoprotein (Stabilized) from SARS-CoV-2, with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from HEK293F Cells


Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells


Spike Glycoprotein (Stabilized) from SARS-CoV-2, BA.2 Lineage (Omicron Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells






















  1. Medina, P. B., et al. “Construction and Application of Biobanks for Infectious Diseases: Focus on SARS-CoV-2.” Innov. Dig. Health Diagn. Bio. 2 (2022): 40-47. doi: 10.36401/IDDB-21-06.
  2. “COVID Data Tracker.” Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Accessed 15 August 2022.

Image:  Colorized transmission electron micrograph of SARS-CoV-2 virus particles (in gold). (NIAID/CC BY 2.0)

View More Highlights